Vericel (NASDAQ:VCEL): A Strong Growth Play With an Improving Technical Setup
Vericel Corp (NASDAQ:VCEL): Growth at a Reasonable Price
TD Cowen Maintains Buy on Vericel, Raises Price Target to $58
Truist Securities Reiterates Buy on Vericel, Raises Price Target to $58
Vericel Corporation 2026 Q2 - Results - Earnings Call Presentation
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $72
Vericel Q2 Earnings Call Highlights
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates
Vericel (NASDAQ:VCEL) Beats Q2 Estimates, Raises Guidance, Shares Rise
Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
Vericel Q2 EPS $0.04 Beats $(0.03) Estimate, Sales $77.457M Beat $72.689M Estimate
Vericel Raises FY2026 Sales Guidance from $326.000M-$336.000M to $330.000M-$340.000M vs $332.199M Est
HC Wainwright & Co. Reiterates Buy on Vericel, Maintains $70 Price Target
Vericel Corp (NASDAQ:VCEL): Strong Growth Stock With a Bull Flag Breakout Setup
Vericel Corp (NASDAQ:VCEL): An Affordable Growth Stock at a Reasonable Valuation
Truist Securities Maintains Buy on Vericel, Raises Price Target to $54
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
Vericel Corp (NASDAQ:VCEL): A Classic Affordable Growth Stock in Biotech
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.